Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

Safety Information

H6541

Sigma-Aldrich

Oncostatin M human

OSM, recombinant, expressed in HEK 293 cells, HumanKine®, suitable for cell culture

Synonym(s):

OSM

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

CAS Number:
106956-32-5
MDL number:
MFCD00166731
UNSPSC Code:
12352202
NACRES:
NA.77

biological source

human

Quality Level

100

recombinant

expressed in HEK 293 cells

Assay

≥95% (SDS-PAGE)

form

lyophilized powder

potency

≤0.1-1.5 ng/mL EC50

quality

endotoxin tested

mol wt

dimer 30 kDa (glycosylated)

packaging

pkg of 5X10 μg
pkg of 10 μg

technique(s)

cell culture | mammalian: suitable

impurities

≤1 EU/μg

UniProt accession no.

P13725

storage temp.

−20°C

Gene Information

human ... OSM(5008)

Looking for similar products? Visit Product Comparison Guide

Biochem/physiol Actions

Oncostatin M (OSM), LIF, G-CSF, IL-6, and CNTF are structurally related members of the same cytokine family sharing similarities in their primary amino acid sequences, predicted secondary structure, and receptor components. OSM is a growth-regulating cytokine, affecting a number of tumor and normal cells. This material was first identified by its ability to inhibit the growth of A375 melanoma cells and other human tumor cells, but not inhibit the growth of normal human fibroblasts. It acts synergistically with TGF β1 to inhibit the proliferation of tumor cells like A375 melanoma cells. It induces an increase in LDL receptor expression and LDL uptake by hepatoma cells. OSM activates synovial fibroblast-like cells to produce urokinase type plasminogen activator. OSM is secreted by macrophages and activated T lymphocytes.

Physical form

Lyophilized from a 0.2 μm filtered solution of 1x PBS.

Analysis Note

The activity was determined by the dose-dependent stimulation of the proliferation of human TF-1 cells (humanerythroleukemic indicator cell line)

Legal Information

HumanKine is a registered trademark of Proteintech Group, Inc. and Humanzyme, Inc

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Regulatory Listings

Regulatory Listings are mainly provided for chemical products. Only limited information can be provided here for non-chemical products. No entry means none of the components are listed. It is the user’s obligation to ensure the safe and legal use of the product.

JAN Code

H6541-BULK:
H6541-10UG:
H6541-10UG-PW:
H6541-5UG:
H6541-VAR:
H6541-5X10UG:

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
MKCQ6453
MKCP3374
MKCN5729
MKCL0836
MKCK1315

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Yuxin Wang et al.
Proceedings of the National Academy of Sciences of the United States of America, 110(42), 16975-16980 (2013-10-02)
The activation of STAT3 by tyrosine phosphorylation, essential for normal development and for a normal inflammatory response to invading pathogens, is kept in check by negative regulators. Abnormal constitutive activation of STAT3, which contributes to the pathology of cancer and
N Kanda et al.
Allergy, 67(6), 804-812 (2012-04-11)
Skin lesions with atopic dermatitis (AD) are associated with dysregulated expression of LL-37 and enhanced expression of IL-22, thymic stromal lymphopoietin (TSLP), IL-25, IL-31, and oncostatin M. Vitamin D3 enhances LL-37 production in keratinocytes. This study aimed to examine the
Andrea Rinaldi et al.
British journal of haematology, 163(2), 194-204 (2013-08-22)
In a fraction of patients, chronic lymphocytic leukaemia (CLL) can transform to Richter syndrome (RS), usually a diffuse large B-cell lymphoma (DLBCL). We studied genome-wide promoter DNA methylation in RS and clonally related CLL-phases of transformed patients, alongside de novo
Vicky Nicolaidou et al.
PloS one, 7(7), e39871-e39871 (2012-07-18)
A major therapeutic challenge is how to replace bone once it is lost. Bone loss is a characteristic of chronic inflammatory and degenerative diseases such as rheumatoid arthritis and osteoporosis. Cells and cytokines of the immune system are known to
Yu-Fan Chen et al.
Hepatology (Baltimore, Md.), 55(4), 1193-1203 (2011-11-19)
Liver transplantation is the only definitive treatment for end-stage cirrhosis and fulminant liver failure, but the lack of available donor livers is a major obstacle to liver transplantation. Recently, induced pluripotent stem cells (iPSCs) derived from the reprogramming of somatic
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service